natgillin/translations-raw huggingface dataset:
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score >9).
Pri bolnikih s hudo okvaro jeter (ocena po Child-Pugh-u >9) uporabe alogliptina niso raziskovali.
Due to its metformin component, Vipdomet should not be used in patients with severe renal impairment, or end-stage renal disease requiring dialysis (see section 4.2).
Pri bolnikih s hudo okvaro ledvic in bolnikih s končno ledvično odpovedjo, ki potrebujejo dializo, se zdravila Vipdomet zaradi vsebnosti metformina ne sme uporabljati (glejte poglavje 4.2).
Each 12.5 mg/1,000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1,000 mg metformin hydrochloride.
Ena 12,5 mg/1.000 mg filmsko obložena tableta vsebuje alogliptinijev benzoat v količini, ki ustreza 12,5 mg alogliptina, in 1.000 mg metforminijevega klorida.
The pharmacokinetics of Vipdomet in children and adolescents <18 years old has not been established.
Farmakokinetika zdravila Vipdomet pri otrocih in mladostnikih, mlajših od 18 let, ni bila raziskana.
More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (0.8%) at Week 26.
V 26. tednu je ciljne vrednosti HbA1c ≤ 7,0 % doseglo več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (7,8 %), v primerjavi z bolniki, ki so prejemali placebo (0,8 %).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
V 26. tednu je ciljne vrednosti HbA1c ≤7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (49,2 %), v primerjavi z bolniki, ki so prejemali placebo (34,0 %) (p=0,004).
becoming breathless - Liver problems (hepatitis or liver function test abnormalities) - Erythema (redness of skin).
- Težave z jetri (vnetje jeter, nenormalni izvidi preiskav delovanja jeter).
However, mean peak plasma concentrations of alogliptin and metformin were decreased by 13% and 28% when Vipdomet was administered with food, respectively.
Vendar pa so se pri uporabi zdravila Vipdomet skupaj s hrano povprečne največje koncentracije alogliptina v plazmi zmanjšale za 13 %, povprečne največje koncentracije metformina v plazmi pa zmanjšale za 28 %.
You should not use Vipdomet if you are pregnant.
Med nosečnostjo zdravila Vipdomet ne smete jemati.
Alogliptin as add-on therapy to metformin with a thiazolidinedione The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
Alogliptin kot dodatek k zdravljenju z metforminom in s tiazolidindionom Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s pioglitazonom (povprečni odmerek = 35,0 mg, v kombinaciji z metforminom ali s sulfonilsečnino ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 2).
- Vipdomet 12.5 mg/1,000 mg film-coated tablets (tablets) are pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
- Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete (tablete) so bledo rumene, podolgovate (približno 22,3 mm dolge in 10,7 mm široke), obojestransko izbočene, filmsko obložene tablete z vtisnjeno oznako “12.5/1000” na eni in “322M” na drugi strani.
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmsko obložene tablete Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete alogliptin/metforminijev klorid
Hepatobiliary disorders hepatitis very rare
zelo redki hipoglikemija pogosti pogosti
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
V 26. tednu je ciljne vrednosti HbA1c ≤7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (44,4 %), v primerjavi z bolniki, ki so prejemali placebo (18,3 %) (p<0,001).
Alogliptin as add-on therapy to metformin with insulin The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 2).
Alogliptin kot dodatek k zdravljenju z metforminom in insulinom Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z insulinom (povprečni odmerek = 56,5 i.e., z metforminom ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 2).
If necessary, the dose of Vipdomet should be adjusted during therapy with the other medicinal product and upon its discontinuation.
Med zdravljenjem in po prekinitvi zdravljenja z drugim zdravilom bo odmerek zdravila Vipdomet morda treba prilagoditi.
How to store Vipdomet
Shranjevanje zdravila Vipdomet
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg tablets alogliptin/metformin hydrochloride
IME ZDRAVILA Vipdomet 12,5 mg/1.000 mg tablete alogliptin/metforminijev klorid
This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies; metformin reduces total cholesterol, LDL cholesterol and triglyceride levels.
To je bilo dokazano ob terapevtskih odmerkih v nadzorovanih srednjeročnih ali dolgoročnih kliničnih študijah.
- Keep this leaflet.
- Izpuščaj.
It is especially important to mention the following: - hydrocortisone and prednisolone (corticosteroids), used to treat diseases that involve inflammation like asthma and arthritis - cimetidine, used to treat stomach problems - bronchodilators (beta-2 agonists), used to treat asthma - medicines which increase urine production (diuretics) - medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib), - certain medicines used for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists) - medicines containing alcohol.
Posebno pomembno je omeniti naslednje: - hidrokortizon in prednizolon (kortikosteroida), ki ju uporabljamo za zdravljenje bolezni, ki vključujejo vnetja, kot sta astma in artritis.
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
IME ZDRAVILA Vipdomet 12,5 mg/850 mg tablete alogliptin/metforminijev klorid
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride.
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 12,5 mg alogliptina (v obliki benzoata) in 850 mg metforminijevega klorida.
NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1,000 mg film-coated tablets
Vipdomet 12,5 mg/850 mg filmsko obložene tablete Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 196 (2x98) film-coated tablets (multipack)
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/026 196 (2x98) filmsko obloženih tablet (večodmerno pakiranje)
No studies in lactating animals have been conducted with the combined active substances of Vipdomet.
Študije s kombinacijo zdravilnih učinkovin zdravila Vipdomet pri živalih med laktacijo niso bile izvedene.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 196 (2x98) film-coated tablets (multipack)
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/025 196 (2x98) filmsko obloženih tablet (večodmerno pakiranje)
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 2x98 film-coated tablets
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/025 2x98 filmsko obloženih tablet
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 1,000 mg metformin hydrochloride.
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 12,5 mg alogliptina (v obliki benzoata) in 1000 mg metforminijevega klorida.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 2x98 film-coated tablets
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/026 2x98 filmsko obloženih tablet
After administration of single oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing.
Največje koncentracije v plazmi so bile dosežene 1 do 2 uri (mediana vrednost Tmax) po odmerku.
- Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough - Rash - Itchy skin with or without hives - Headache - Indigestion, heartburn - Vomiting and/or diarrhoea - Metallic taste.
- Prehladu podobni simptomi, kot so boleče žrelo, zamašen nos, občutek utrujenosti, zvišana telesna temperatura, mrzlica, suh kašelj.
Other reactions such as upper respiratory tract infections, nasopharyngitis, headache, gastroenteritis, abdominal pain, diarrhoea, vomiting, gastritis, gastroesophageal reflux disease, pruritus, rash, hypoglycaemia may occur commonly (≥ 1/100 to < 1/10) (see section 4.4) which are attributed to Vipdomet.
Laktacidoza je resna neželena reakcija, ki se pojavlja zelo redko (<1/10.000) in ki jo je mogoče pripisati vsebnosti metformina v zdravilu Vipdomet (glejte poglavje 4.4).Pogosto (≥1/100 do <1/10) se pojavijo tudi druge reakcije, kot so okužbe zgornjih dihal, nazofaringitis, glavobol, gastroenteritis, bolečina v trebuhu, driska, bruhanje, gastritis, gastroezofagealni refluks, srbenje, izpuščaj, hipoglikemija (glejte poglavje 4.4), ki so posledica uporabe zdravila Vipdomet.
Your blood sugar levels may increase when you stop taking Vipdomet.
Po prenehanju jemanja zdravila Vipdomet se vrednost krvnega sladkorja lahko zviša.
Vipdomet 12.5 mg/850 mg film-coated tablets
Vipdomet 12,5 mg/850 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/1,000 mg film-coated tablets
Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet is not recommended for children and adolescents under 18 years due to the lack of data in these patients.
Zaradi pomanjkanja podatkov uporaba zdravila Vipdomet pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
For patients inadequately controlled on dual therapy with a maximal tolerated dose of metformin and pioglitazone, the dose of pioglitazone should be maintained, and Vipdomet administered concomitantly; alogliptin should be dosed at 12.5 mg twice daily (25 mg total daily dose) and metformin hydrochloride at a similar dose (either 850 mg or 1,000 mg twice daily) to that already being taken.
Odmerek alogliptina mora biti 12,5 mg dvakrat na dan (skupni dnevni odmerek 25 mg), odmerek metforminijevega klorida pa enak tistemu, ki ga bolnik že jemlje (850 mg ali 1.000 mg dvakrat na dan).
Pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
Vipdomet 12,5 mg/1000 mg filmsko obložene tablete Bledo rumene, podolgovate (približno 22,3 mm dolge in 10,7 mm široke), bikonveksne, filmsko obložene tablete z vtisnjeno oznako “12.5/1000” na eni in “322M” na drugi strani.
Film-coating
Bruhanje.
The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s 30 mg pioglitazona in z metforminijevim kloridom (povprečni odmerek = 1.867,9 mg) je v 52. tednu povzročil izboljšanja glede na izhodiščne vrednosti HbA1c.
The following section outlines the interactions observed with the individual components of Vipdomet (alogliptin/metformin) as reported in their respective Summary of Product Characteristics.
(alogliptin/metformin), kot so navedena v njunih povzetkih glavnih značilnosti zdravila.
Light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
Vipdomet 12,5 mg/850 mg filmsko obložene tablete Svetlo rumene, podolgovate (približno 21,0 mm dolge in 10,1 mm široke), bikonveksne, filmsko obložene tablete z vtisnjeno oznako “12.5/850” na eni in “322M” na drugi strani.
This summary was last updated in October 2008.
Ta povzetek je bil nazadnje posodobljen 10-2008.
In some cases fever may occur for one day, and up to three days in exceptional circumstances.
V nekaterih primerih se lahko pojavi vročina, ki traja en dan, v izjemnih okoliščinah pa do treh dni.
All studies were performed with Equilis Prequenza Te (comment: double; mentioned in next paragraph).
Vse študije so izvedli z zdravilom Equilis Prequenza Te (komentar: dvojno; omenjeno v naslednjem odstavku).
Other information about Equilis Te:
Druge informacije o zdravilu Equilis Te:
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Te to Intervet International BV on 8 July 2005.
Evropska komisija je dovoljenje za promet z zdravilom Equilis Te, veljavno po vsej Evropski uniji, odobrila družbi Intervet International BV dne 8. julija 2005.
Afterwards, a maximum interval of two years is recommended.
Po tem je najdaljši priporočeni razmik dve leti.
The vaccine also contains an ‘adjuvant' to stimulate a better immune response.
Cepivo vsebuje tudi „adjuvans“, ki spodbudi boljši imunski odziv.
The Committee recommended that Equilis Te should be given a marketing authorisation.
Odbor je priporočil, da se za zdravilo Equilis Te odobri dovoljenje za promet.
When the product is given to horses, it helps the animals' immune system to react quicker when the animal is naturally exposed to the Clostridium tetani bacterium.
Kadar se zdravilo daje konjem, pomaga imunskemu sistemu živali, da reagira hitreje, ko je žival naravno izpostavljena bakteriji Clostridium tetani.
To retain protection against tetanus, horses need to be revaccinated.
Za ohranitev zaščite proti tetanusu morajo biti konji ponovno cepljeni.
The duration of protection against tetanus was 17 months after primary vaccination and 24 months after the first revaccination.
Trajanje zaščite proti tetanusu je bilo 17 mesecev po osnovnem cepljenju in 24 mesecev po prvem ponovnem cepljenju.
Horses should receive a primary vaccination, consisting of two injections given four weeks apart.
Konji potrebujejo osnovno cepljenje, ki vključuje dve injiciranji, ki se izvedeta štiri tedne narazen.
The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles.
Za bolezen, ki navadno izvira iz okuženih ran, so značilni rigidnost (otrdelost) celotnega telesa in sunkoviti krči mišic.
Horses developed protection two weeks after primary vaccination.
Konji so razvili zaščito dva tedna po osnovnem cepljenju.
It was concluded that the product is well tolerated by horses of different age.
Sklenili so, da zdravilo dobro prenašajo konji različnih starosti.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the doctor.
Če pride do nenamernega samoinjiciranja, se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali nalepko.
What is the risk associated with Equilis Te?
Kakšna tveganja so povezana z zdravilom Equilis Te?
The toxoid is a toxin processed in order to remove its toxic effect, but retain its antigenic properties.
Toksoid je toksin, obdelan tako, da odpravi učinek strupa, toda ohrani svoje antigenske lastnosti.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
Koliko časa mora preteči, preden se lahko žival zakolje in meso uporabi za prehrano ljudi (obdobje karence)?
The effectiveness of Equilis Te has been studied in several trials under laboratory and field conditions.
Učinkovitost zdravila Equilis Te so raziskali v več preskušanjih, izvedenih v laboratorijskih in terenskih pogojih.
The safety of Equilis Te was studied in several studies under laboratory and field conditions in a large number of horses, from 2 months of age.
Varnost zdravila Equilis Te so raziskovali v več študijah, izvedenih v laboratorijskih in terenskih pogojih na številnih konjih, starejših od 2 mesecev.
Equilis Te is a vaccine for use in horses.
Zdravilo Equilis Te je cepivo, ki se uporablja za konje.
The first revaccination should be no later than 17 months after primary vaccination.
Prvo ponovno cepljenje se mora izvesti najpozneje v 17 mesecih po osnovnem cepljenju.
Horses belong to the most susceptible species to tetanus.
Konji so med živalskimi vrstami najbolj občutljivi na tetanus.
What benefit has Equilis Te shown during the studies?
Kakšne koristi je zdravilo Equilis Te izkazalo med študijami?
Studies in pregnant mares were also performed.
Študije so izvedli tudi na brejih kobilah.
The main measure of effectiveness was the production of protective levels of antibodies against tetanus toxoid after vaccination.
Glavno merilo učinkovitosti je bilo tvorjenje zaščitnih ravni protiteles proti toksoidu tetanusa po cepljenju.
Pain at the injection site can occur occasionally.
Občasno je možna bolečina na mestu dajanja.
Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani.
Tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin, ki ga proizvaja bakterija Clostridium tetani.
This helps to protect against tetanus.
S tem pomagamo zaščititi žival proti tetanusu.
Equilis Te is a vaccine containing purified tetanus toxoid.
Zdravilo Equilis Te je cepivo, ki vsebuje prečiščen toksoid tetanusa.
Why has Equilis Te been approved?
Zakaj je bilo zdravilo Equilis Te odobreno?
It contains the toxoid (chemically inactivated toxin) from the tetanus bacterium.
Vsebuje toksoid (kemično oslabljen toksin) iz bakterije tetanusa.
Most of the studies were performed with Equilis Prequenza Te, a vaccine that protects against equine influenza as well as against tetanus.
Večino študij so izvedli z zdravilom Equilis Prequenza Te, cepivom, ki ščiti tako proti influenci konj kot tudi proti tetanusu.
The studies showed that Equilis Te is an effective vaccine against tetanus to prevent mortality in horses from 6 months of age.
Študije so pokazale, da je zdravilo Equilis Te učinkovito cepivo proti tetanusu za preprečevanje umrljivosti pri konjih, ki so starejši od 6 mesecev.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Te exceeded the risks for the immunisation of horses from six months of age against tetanus to prevent mortality.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Equilis Te pri imunizaciji konj, ki so starejši od šest mesecev, proti tetanusu za preprečevanje umrljivosti večje od z njim povezanih tveganj.
Swelling (max. diameter 5 cm) may occur at the injection site, either as diffuse hard or soft swelling.
Lahko se pojavi neostro omejena trda ali mehka oteklina (premera največ 5 cm) na mestu dajanja.
Equilis Te is used to vaccinate horses from six months of age against tetanus to prevent mortality.
Zdravilo Equilis Te se uporablja za cepljenje konj, ki so starejši od šestih mesecev, proti tetanusu za preprečevanje umrljivosti.
No negative influence on gestation, foaling and offspring of mares was observed after vaccination at different times during pregnancy.
Po cepljenju v različnih obdobjih brejosti niso opazili nobenih negativnih učinkov na brejost, žrebitev in mladiče.
How has Equilis Te been studied?
Kako je bilo zdravilo Equilis Te raziskano?
How does Equilis Te work?
Kako zdravilo Equilis Te deluje?
What is Equilis Te used for?
Za kaj se zdravilo Equilis Te uporablja?
What is Equilis Te?
Kaj je zdravilo Equilis Te?
The withdrawal period of the product is zero days.
Obdobje karence zdravila je nič dni.
If the symptoms persist for more than 2 weeks, a doctor or a qualified health care practitioner should be consulted.
Če simptomi trajajo dlje kot 2 tedna, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
Fresh bilberry fruit EMA/680058/2015
Svež plod borovnice EMA/680058/2015
In its assessment, the HMPC also considered clinical studies on disorders of the circulatory system which were performed 30 - 40 years ago.
V svoji oceni je odbor HMPC prav tako upošteval klinične študije o motnjah obtočil, ki so bile izvedene pred 30-40 leti.
Fresh bilberry fruit medicines should only be used in adults and should not be taken for longer than 4 weeks.
Zdravila, ki vsebujejo svež plod borovnice, se smejo uporabljati samo pri odraslih in se ne smejo uporabljati več kot 4 tedne.
This summary is not intended to provide practical advice on how to use medicines containing fresh bilberry fruit.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo svež plod borovnice.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of fresh bilberry fruit.
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo svežega plodu borovnice.
Although possible beneficial effects were observed, there were limitations in the way the studies were conducted and, therefore, the HMPC conclusions on the use of fresh bilberry fruit medicines are based on their long-standing use.
Čeprav so bili ugotovljeni možni koristni učinki, so bile pri izvedbi študij pomanjkljivosti in zato zaključki odbora HMPC v zvezi z uporabo zdravil, ki vsebujejo svež plod borovnice, temeljijo na njihovi dolgotrajni uporabi.
Further information on the risks associated with fresh bilberry fruit medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo svež plod borovnice, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Fresh bilberry fruit
Svež plod borovnice
Herbal medicines containing fresh bilberry fruit preparations are usually available in solid forms to be taken by mouth.
Zdravila rastlinskega izvora, ki vsebujejo pripravke s svežim plodom borovnice, so navadno na voljo v trdni obliki za jemanje skozi usta.
Fresh bilberry fruit is the common name for the fresh fruit of the plant Vaccinium myrtillus L. Fresh bilberry fruit preparations are obtained using a technique to extract compounds from fresh plant material by dissolving them in a solvent (such as methanol), which is then evaporated to obtain a dry extract.
Svež plod borovnice je splošno ime za svež plod rastline Vaccinium myrtillus L. Pripravki s svežim plodom borovnice se pridobivajo z uporabo tehnike, s katero se spojine ekstrahirajo tako, da se svež rastlinski material najprej namoči v topilo (npr. metanol), v katerem se raztopijo spojine.
The anthocyanins are also thought to repair tiny blood vessels after damage to the local circulation.
Antocianini naj bi prav tako popravljali kapilare po poškodbi lokalnega obtoka.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing fresh bilberry fruit.
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo svež plod borovnice.
What is fresh bilberry fruit?
Kaj je svež plod borovnice?